Target intelligence / Profile preview

Ubiquitous surface protein A2 (UspA2) (UspA2)

Target
UspA2
Molecular classification
Trimeric autotransporter adhesin, Outer membrane protein, Bacterial adhesin
01

Overview

Ubiquitous surface protein A2 (UspA2) is a major outer membrane protein of the Gram-negative bacterium Moraxella catarrhalis, which is a significant human respiratory pathogen. As a member of the trimeric autotransporter adhesin (TAA) family, UspA2 is essential for the bacterium's ability to adhere to human epithelial cells and survive in the host environment. One of its primary roles is providing serum resistance by binding to complement inhibitors like C4b-binding protein and vitronectin, effectively neutralizing the host's innate immune response. Because of its critical role in virulence and its presence in nearly all clinical isolates, UspA2 is a leading target for vaccine development aimed at preventing otitis media in children and exacerbations of chronic obstructive pulmonary disease (COPD) in adults. Current therapeutic efforts, such as those by GlaxoSmithKline, involve using recombinant UspA2 fragments to elicit protective, bactericidal antibodies (, NCT03318042). These vaccine candidates are designed to induce high titers of IgG that block bacterial attachment and facilitate clearance by the immune system. Despite its potential, challenges remain regarding the antigenic variation observed among different strains of M. catarrhalis.

Other names
UspA2Moraxella catarrhalis UspA2Trimeric autotransporter adhesin UspA2
02

Mechanism of action

Vaccine-induced production of neutralizing and bactericidal antibodies that block bacterial adhesion to host cells and inhibit complement evasion mechanisms.

03

Biological functions

Cell adhesionSerum resistanceComplement system evasionExtracellular matrix binding
04

Disease associations

Otitis mediaChronic obstructive pulmonary disease (COPD) exacerbationSinusitisPneumoniaInfection
05

Safety considerations

Antigenic variation among strainsPotential for limited cross-reactivityAdjuvant-related reactogenicity in vaccine formulations
06

Interacting drugs

GSK Moraxella catarrhalis vaccine (GSK2745223A)

1 more in the full profile.

07

Biomarkers

Anti-UspA2 IgG antibody titersSerum bactericidal activity (SBA) (, NCT03318042)

Source types: Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Ubiquitous surface protein A2 (UspA2) (UspA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitous surface protein A2 (UspA2) (UspA2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call